Arm A,Arm B

2 trials

Sponsors

Bhumibol Adulyadej Hospital, Taiho Pharmaceutical Co., Ltd.

Conditions

Patients with First-Line Advanced Biliary Tract Cancers Biliary Tract Cancerspost-embolization syndrome TACE HCC HCC TACE Post-embolization syndrome Dexamethazone Parecoxib

Phase 3

Randomized-controlled, open label, parallel groups, global phase 3 study design in patients with first-line advanced biliary tract cancer

Active, not recruitingTCTR20260616001

Taiho Pharmaceutical Co., Ltd.Patients with First-Line Advanced Biliary Tract Cancers Biliary Tract Cancers

Start: 2026-09-01Target: 784Updated: 2026-08-03

Phase 4

Efficacy and Safety of Low-Dose Intravenous Dexamethasone and Parecoxib in prevention of post embolization syndrome

RecruitingTCTR20260608003

Bhumibol Adulyadej Hospitalpost-embolization syndrome TACE HCC HCC TACE Post-embolization syndrome Dexamethazone Parecoxib

Start: 2026-05-29Target: 144Updated: 2026-08-03